We may therefore speculate that MEK/ERK pathway inhibition induces molecular reprogramming, which rescues the myogenic precursor phenotype in rhabdomyosarcoma cancer stem-like cells. This evidence concerns the gene MAP2K7 and rhabdomyosarcoma.